St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products

SAN ANTONIO--(BUSINESS WIRE)--Santalis Pharmaceuticals Inc., a joint venture with TFS Corporation Ltd., of Australia (ASX: TFC) is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of a number of over-the-counter (OTC) dermatology products containing TFS’ sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO). The pharmaceutical partner is exclusively dedicated to dermatology and is a world leader in dermatology products with an extensive product portfolio available in 80 countries. The long-term license agreement provides for upfront and milestone payments and royalties based on product sales. The license agreement anticipates worldwide commercialization of the OTC products, with an initial product launch in the U.S. anticipated at the end of 2014.

In addition to its OTC products, Santalis is developing a range of prescription drug candidates. The company’s first prescription drug candidate, a topical formulation of EISO to treat pediatric eczema, is expected to enter the clinic in the US in early 2015.

Dr. Paul Castella, Santalis' CEO, stated, “This agreement is an important milestone for our product and clinical development program, and has been achieved just three years into our joint venture with TFS. The quality of our pharmaceutical partner, their longstanding dedication to patient wellbeing, and their ambitions for the products in the marketplace are a testament to the efficacy and clinical benefit of sustainable sandalwood oil-based products in the treatment of important dermatological conditions.”

Mr. Frank Wilson, CEO of TFS said "Santalis’ agreement with a leading pharmaceutical partner is the first of many such product opportunities, and validates the value of EISO as a natural ingredient in the rapidly expanding global market for dermatology, which is currently estimated to exceed $20B. Our long term, exclusive supply agreement with Santalis was pivotal to their ability to secure the commitment of a world-class partner.”

ABOUT SANTALIS
Santalis Pharmaceuticals, Inc., a 50:50 joint venture with TFS Corporation, Ltd., of Australia, is developing scientifically and clinically validated healthcare products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian Sandalwood Oil (EISO). Santalis’ initial product offerings are focused in dermatology, where EISO’s well documented anti-microbial, anti-inflammatory and non-irritating properties are expected to be particularly well suited to a number of prevalent and under-served conditions (such as acne, eczema, redness and sensitive skin).

ABOUT TFS
TFS Corporation Ltd (ASX: TFC) is an owner and manager of the world’s largest East Indian sandalwood plantations. TFS’ first planting in northern Australia was in 1999 and it now manages approximately 7,600 hectares on behalf of both retail and institutional investors. TFS is committed to adopting and maintaining the highest environmental and ethical standards in all aspects of its business and is ranked as an industry leader in ethical and sustainable practices by Oekom Research, a leading international ratings agency. In 2009, TFS entered the prestigious Forbes Asia Pacific's ‘Best Under a Billion’, which recognizes the Top 200 companies from more than 25,326 publicly-listed firms in the Asia/Pacific region with revenue of less than $1 billion.

CONTACTS
Santalis Pharmaceuticals Inc.
Dr. Paul Castella, CEO, 210-399-2316
paul@santalispharma.com back

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more